Johnson & Johnson
JNJ$256.98
$-0.61 (-0.24%)-0.24%
ClosedGoldman Sachs removed Johnson & Johnson from its U.S. Conviction List in its August reshuffle of top stock ideas.
Loading chart...
IndexN/A
Market Cap619.30B
Enterprise Value532.30B
Income$26.80B
Sales$94.19B
Employees138,100
P/E23.95
P/S5.35
P/B6.18
P/C25.59
EV/EBITDA12.97
EV/Sales19.53
EPS (ttm)10.73
Earnings2025-10-14
Gross Margin66.40%
Oper. Margin28.77%
Profit Margin50.24%
Volume4.30M
Shs Outstand2.41B
Change-0.24%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD5.45%
Perf Year48.72%
Perf 3Y26.86%
Perf 5Y34.33%
Perf 10Y124.27%
IPO1943-01-02
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B |
| Cost of Revenue | $25.64B | $27.47B | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B | $27.09B |
| Gross Profit | $68.56B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B |
| Gross Margin | 72.78% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% |
| Operating Expenses | $42.96B | $39.20B | $35.20B | $34.38B | $34.40B | $34.42B | $33.53B | $33.31B |
| Operating Income | $25.60B | $22.15B | $23.41B | $21.01B | $20.94B | $19.73B | $20.97B | $21.18B |
| Operating Margin | 27.17% | 24.94% | 27.49% | 26.27% | 26.60% | 23.89% | 25.55% | 25.96% |
| Net Income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B |
| Net Margin | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% |
| EPS (Basic) | $0.00 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.74 | $5.75 |
| EBITDA | N/A | $24.78B | $23.32B | $26.61B | $26.75B | $23.93B | $24.66B | $25.93B |
| Stock Option Compensation Expense | N/A | $1.18B | $1.16B | $1.14B | $1.14B | $1.00B | $977.00M | $978.00M |
| Price To Earnings Ratio | N/A | 24.53 | 11.30 | 25.73 | 21.54 | 28.16 | 25.40 | 22.46 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | $345.06B | $397.10B | $461.69B | $449.74B | $414.30B | $384.00B | $343.57B |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $0.00 | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $0.00 | $108.61B | $98.78B | $110.57B | $108.00B | $111.62B | $98.26B | $93.20B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $0.00 | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $0.00 | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B |
| Total Liabilities & Stockholders Equity | $0.00 | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B |
| Book Value Per Share | N/A | $29.70 | $27.15 | $29.39 | $28.16 | $24.04 | $22.59 | $22.44 |
| Tangible Book Value Per Share | N/A | $-4.29 | $-0.77 | $0.87 | $-2.90 | $-10.07 | $-8.29 | $-6.88 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | 7.81% | 20.98% | 9.57% | 11.47% | 8.41% | 9.59% | 10.00% |
| Return on Equity | N/A | 19.68% | 51.11% | 23.36% | 28.20% | 23.25% | 25.42% | 25.60% |
| Return on Invested Capital | N/A | 13.75% | 16.61% | 12.31% | 13.83% | 13.03% | 14.88% | 14.45% |
| Quick Ratio | N/A | 0.86 | 0.91 | 0.81 | 1.12 | 0.99 | 1.01 | 1.20 |
| Current Ratio | N/A | 1.11 | 1.16 | 0.99 | 1.35 | 1.21 | 1.26 | 1.47 |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B |
| Depreciation | N/A | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B | $6.93B |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $0.00 | $24.27B | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B | $22.20B |
| Capital Expenditures | N/A | $4.42B | $4.54B | $4.01B | $3.65B | $3.35B | $3.50B | $3.67B |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | $11.82B | $11.77B | $11.68B | $11.03B | $10.48B | $9.92B | $9.49B |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | $2.43B | $5.05B | $6.04B | $3.46B | $3.22B | $6.75B | $5.87B |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | $19.84B | $18.25B | $17.18B | $19.76B | $20.19B | $19.92B | $18.53B |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
How to Build $8,500 a Month in Dividend Income Without Selling a Single Share247wallst.com Johnson & Johnson Is Spending $1 Billion to Make More Contact Lenses. Medicare Covers Them in Only One Narrow Situation.247wallst.com Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night.fool.com 5 Solid Dividend Stocks to Buy in August247wallst.com The Market Is Flashing a Valuation Warning -- but History Shows These Stocks Can Handle the Turbulencefool.com Avior Wealth Management LLC Sells 4,587 Shares of Johnson & Johnson $JNJdefenseworld.net The Dividend Income Illusion: Why Your 8% Yield Is Really Paying You 5%247wallst.com 3 Dividend Stocks Built for Retirement to Buy in August247wallst.com
Show 12 more stories
Dividends vs. an Annuity: Which Turns $675,000 Into More Monthly Income for Life?247wallst.com How Much Do You Really Need Invested to Replace a $100,000 Salary With Dividends?247wallst.com Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conferencebusinesswire.com 4 Non-Tech Stocks to Grab as Dow Hits New Milestone Amid AI Sell-offzacks.com Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective Septemberbusinesswire.com 5 Dividend Stocks Every Boomer Should Own Heading Into Fall247wallst.com Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcriptseekingalpha.com J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopeszacks.com Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?zacks.com Johnson & Johnson's OTTAVA Robotic Surgery System Targets Long-Term Growthmarketbeat.com Johnson & Johnson $JNJ Shares Sold by FAS Wealth Partners Inc.defenseworld.net First National Bank of Mount Dora Trust Investment Services Sells 2,499 Shares of Johnson & Johnson $JNJdefenseworld.net
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Discover more
You may be interested in